Who Qualifies for GLP-1 Medications? Complete Eligibility Criteria for 2026

FDA approval criteria, insurance requirements, Medicare's new $50/month GLP-1 Bridge launching July 2026, and every BMI threshold and qualifying condition — with the actual sources behind each one.

GLP-1 eligibility is one of the most-searched questions in weight loss medicine, and for good reason — the rules differ depending on whether you're talking about FDA-approved indications, private insurance formularies, employer programs, or Medicare's new coverage pathway. This guide breaks down each layer with the specific thresholds and qualifying conditions that actually matter.

The Two FDA-Approved BMI Thresholds

The baseline eligibility criteria for GLP-1 medications prescribed for weight management come directly from their FDA-approved labeling. There are two pathways: FDA Label

These are the thresholds for Wegovy (semaglutide) and Zepbound (tirzepatide) when prescribed specifically for chronic weight management. For GLP-1 medications prescribed for type 2 diabetes — such as Ozempic or Mounjaro — different criteria apply based on glycemic control rather than BMI.

Which Conditions Qualify at BMI 27–29.9?

If your BMI falls in the "overweight" range, you can still qualify if you have at least one of the following:

What About Waist Circumference?

Some clinicians use waist circumference as supplementary evidence when BMI is borderline. The thresholds associated with elevated metabolic risk are 40 inches or greater in men and 35 inches or greater in women. While waist circumference is not explicitly part of the FDA label, it strengthens prior authorization requests to insurance companies because it correlates with insulin resistance and visceral adiposity — conditions that GLP-1 medications directly address.

FDA-Approved Medications by Indication

Not every GLP-1 is approved for the same thing. This matters for insurance coverage — your plan may cover Ozempic for diabetes but reject it for weight loss.

Wegovy is currently the only GLP-1 approved for adolescents (ages 12–17) who meet the criteria for obesity. FDA.gov

Medicare GLP-1 Bridge: New Coverage Starting July 2026

For the first time, Medicare will cover GLP-1 medications specifically for weight management. The Medicare GLP-1 Bridge launches July 1, 2026, and runs through December 31, 2027. CMS.gov

The Medicare GLP-1 Bridge has three distinct eligibility tiers. You only need to meet one:

Tier 1: BMI ≥ 35

No additional qualifying conditions required beyond obesity itself.

Tier 2: BMI ≥ 30 with specific conditions

Must have at least one of: heart failure with preserved ejection fraction (HFpEF), uncontrolled hypertension on 2 or more medications, or chronic kidney disease Stage 3a or higher.

Tier 3: BMI ≥ 27 with specific conditions

Must have: prediabetes (as defined by ADA guidelines), prior heart attack, prior stroke, or symptomatic peripheral artery disease.

Your prescribing provider submits a prior authorization to a central processor run by CMS — not to your individual Part D plan. The criteria are evaluated based on your BMI at the time you started GLP-1 therapy, not your current BMI. So if you started at BMI 37 and have since dropped to 34, you still qualify under Tier 1.

Private Insurance: Common Requirements

Private insurance requirements vary widely by carrier and employer plan. However, most formularies that cover GLP-1s for weight management require some combination of the following:

Prior authorization from your prescribing provider, documentation of BMI meeting the FDA threshold (30+ or 27+ with comorbidity), evidence of previous weight loss attempts — typically 3 to 6 months of documented diet and exercise, and enrollment in or commitment to a lifestyle modification program. Some insurers also require step therapy, meaning you must try and fail a less expensive medication (such as phentermine or contrave) before they will approve a GLP-1.

The Affordable Care Act does not mandate coverage of anti-obesity medications, so self-funded employer plans have full discretion. Coverage continues to expand — but it is not universal.

Who Does Not Qualify

GLP-1 medications are not appropriate for everyone. The following are contraindications established in the FDA labeling:

Telehealth vs. In-Person: Does It Affect Eligibility?

The clinical eligibility criteria are the same whether you see a provider in person or via telehealth. However, telehealth providers — particularly cash-pay platforms — often have more flexible documentation requirements because they are not processing insurance prior authorizations. Many require only a self-reported height and weight, a brief medical history questionnaire, and a video consultation with a licensed prescriber.

This does not mean the medical criteria do not apply. A responsible telehealth provider will still evaluate BMI, screen for contraindications, and confirm that the medication is clinically appropriate. The difference is that the process is typically faster and does not involve the multi-step prior authorization process that insurance-covered prescriptions require.